Search Results | Molecular Cancer Therapeutics | American Association for Cancer Research

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Luxeptinib (CG-806) targets FLT3 and clusters of kinases operative in acute myeloid leukemia

William G. Rice, Stephen B. Howell, Hongying Zhang, Nasrin Rastgoo, Andrea Local, Stephen E. Kurtz, Pierrette Lo, Daniel Bottomly, Beth Wilmot, Shannon K. McWeeney, Brian J. Druker, Jeffrey W. Tyner

Mol Cancer Ther molcanther.0832.2021.

DOI: https://doi.org/10.1158/1535-7163.MCT-21-0832

Published: 02 May 2022

View article

Includes: Supplementary data

Journal Articles

APTO-253 Stabilizes G-quadruplex DNA, Inhibits MYC Expression, and Induces DNA Damage in Acute Myeloid Leukemia Cells

Andrea Local, Hongying Zhang, Khalid D. Benbatoul, Peter Folger, Xia Sheng, Cheng-Yu Tsai, Stephen B. Howell, William G. Rice

Mol Cancer Ther (2018) 17 (6): 1177–1186.

DOI: https://doi.org/10.1158/1535-7163.MCT-17-1209

Published: 31 May 2018

View article

Includes: Supplementary data

Journal Articles

APTO-253 Is a New Addition to the Repertoire of Drugs that Can Exploit DNA BRCA1/2 Deficiency

Cheng-Yu Tsai, Si Sun, Hongying Zhang, Andrea Local, Yongxuan Su, Larry A. Gross, William G. Rice, Stephen B. Howell

Mol Cancer Ther (2018) 17 (6): 1167–1176.

DOI: https://doi.org/10.1158/1535-7163.MCT-17-0834

Published: 31 May 2018

View article

Includes: Supplementary data

Journal Articles

A6 Peptide Activates CD44 Adhesive Activity, Induces FAK and MEK Phosphorylation, and Inhibits the Migration and Metastasis of CD44-Expressing Cells

Randolph S. Piotrowicz, Bassam B. Damaj, Mohamed Hachicha, Francesca Incardona, Stephen B. Howell, Malcolm Finlayson

Mol Cancer Ther (2011) 10 (11): 2072–2082.

DOI: https://doi.org/10.1158/1535-7163.MCT-11-0351

Published: 08 November 2011

View article

Journal Articles

Recombinant CPE fused to tumor necrosis factor targets human ovarian cancer cells expressing the claudin-3 and claudin-4 receptors

Xiaoqin Yuan, Xinjian Lin, Gerald Manorek, Isao Kanatani, Lawrence H. Cheung, Michael G. Rosenblum, Stephen B. Howell

Mol Cancer Ther (2009) 8 (7): 1906–1915.

DOI: https://doi.org/10.1158/1535-7163.MCT-09-0106

Published: 14 July 2009

View article

Journal Articles

DNA mismatch repair and p53 function are major determinants of the rate of development of cisplatin resistance

Xinjian Lin, Stephen B. Howell

Mol Cancer Ther (2006) 5 (5): 1239–1247.

DOI: https://doi.org/10.1158/1535-7163.MCT-05-0491

Published: 26 May 2006

View article

Journal Articles

Abnormal lysosomal trafficking and enhanced exosomal export of cisplatin in drug-resistant human ovarian carcinoma cells

Roohangiz Safaei, Barrett J. Larson, Timothy C. Cheng, Michael A. Gibson, Shinji Otani, Wiltrud Naerdemann, Stephen B. Howell

Mol Cancer Ther (2005) 4 (10): 1595–1604.

DOI: https://doi.org/10.1158/1535-7163.MCT-05-0102

Published: 14 October 2005

View article

NARROW

Luxeptinib (CG-806) targets FLT3 and clusters of kinases operative in acute myeloid leukemia

APTO-253 Stabilizes G-quadruplex DNA, Inhibits MYC Expression, and Induces DNA Damage in Acute Myeloid Leukemia Cells

APTO-253 Is a New Addition to the Repertoire of Drugs that Can Exploit DNA BRCA1/2 Deficiency

A6 Peptide Activates CD44 Adhesive Activity, Induces FAK and MEK Phosphorylation, and Inhibits the Migration and Metastasis of CD44-Expressing Cells

Recombinant CPE fused to tumor necrosis factor targets human ovarian cancer cells expressing the claudin-3 and claudin-4 receptors

DNA mismatch repair and p53 function are major determinants of the rate of development of cisplatin resistance

Abnormal lysosomal trafficking and enhanced exosomal export of cisplatin in drug-resistant human ovarian carcinoma cells

Email alerts

AACR Journals

Luxeptinib (CG-806) targets FLT3 and clusters of kinases operative in acute myeloid leukemia

APTO-253 Stabilizes G-quadruplex DNA, Inhibits MYC Expression, and Induces DNA Damage in Acute Myeloid Leukemia Cells

APTO-253 Is a New Addition to the Repertoire of Drugs that Can Exploit DNA BRCA1/2 Deficiency

A6 Peptide Activates CD44 Adhesive Activity, Induces FAK and MEK Phosphorylation, and Inhibits the Migration and Metastasis of CD44-Expressing Cells

Recombinant CPE fused to tumor necrosis factor targets human ovarian cancer cells expressing the claudin-3 and claudin-4 receptors

DNA mismatch repair and p53 function are major determinants of the rate of development of cisplatin resistance

Abnormal lysosomal trafficking and enhanced exosomal export of cisplatin in drug-resistant human ovarian carcinoma cells

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only